



## UvA-DARE (Digital Academic Repository)

### Age-dependent impact of early-life stress on glia and synapses

*Substrates for increased risk for Alzheimer's disease*

Kotah, J.M.

#### Publication date

2023

[Link to publication](#)

#### Citation for published version (APA):

Kotah, J. M. (2023). *Age-dependent impact of early-life stress on glia and synapses: Substrates for increased risk for Alzheimer's disease*. [Thesis, fully internal, Universiteit van Amsterdam].

#### General rights

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

#### Disclaimer/Complaints regulations

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <https://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

**CHAPTER 1**



# Introduction



## Age-dependent impact of early-life stress on glia and synapses: Substrates for increased risk for Alzheimer's disease

### Rationale and aim

Early-life stress (ES) exposure has lasting consequences for later-life health and disease, and is associated, based on both pre-clinical and epidemiological data, with increased rates of later cognitive decline<sup>1-3</sup>, psychopathology<sup>4,5</sup> and metabolic disorders<sup>6,7</sup>. This link between early-life experience and later-life health is perhaps most intriguingly observed in Alzheimer's disease (AD), a yet-uncurable, age-associated neurodegenerative condition that is the leading cause of dementia in an aging global population<sup>8,9</sup>. Epidemiological evidence indeed shows that exposure to various forms of ES is associated with an increased risk for dementia and AD<sup>10-14</sup>.

This association with ES provides another piece to the puzzle of AD etiology, whose incidence is also associated with lifetime stress exposure<sup>15,16</sup>. While much attention has been paid to the causal role of the characteristic neuropathological features of AD in its etiology<sup>17,18</sup> (especially amyloid-beta [A $\beta$ ] plaques<sup>19</sup>), they do not account for the majority of cases, which are non-familial, or "sporadic", in nature<sup>20</sup>. This is further reflected by the recent lack of success of A $\beta$ -based clinical trials to improve AD symptomatology<sup>18</sup>. This has opened up studies into additional risk factors like environmental and lifestyle factors that also contribute to disease risk<sup>15,16,21-23</sup> and new biomarkers of the disease, that can potentially be targeted<sup>24-27</sup>.

Accordingly, the link between ES and AD can be viewed within the framework of the developmental origins of health and disease (DOHAD) hypothesis<sup>11,28-30</sup>. As a field that emerged following observations of a link between birthweight and later-life ischemia<sup>31</sup>, much emphasis is placed here on how early programming can lastingly alter development, and thereby later-life health<sup>32</sup>. Such a view has also been proposed for AD-associated risks, whether it be from changes occurring during critical developmental windows, the cumulative aggregation of lifetime insults that only manifest in disease, or from lasting shifts in the organism's entire developmental trajectory<sup>11,33</sup>. Similarly, ES is also thought to lead to differential responses to later-life challenges, which rodent studies show evidence for<sup>34-37</sup>. Given the significant time delay between experiencing ES and the eventual emergence of an increased disease vulnerability, a common question in the field is whether this programming occurs via ES modulation of the aging process itself<sup>5</sup>.

To fully understand these mechanisms behind early-life programming of later AD risk, it is crucial to understand the neurobiological substrates that are affected by ES. At the cellular level, AD is characterized by progressive synaptic loss that is associated with cognitive deficits<sup>38-41</sup>, and neuroinflammatory activation of astrocytes and microglia that lead to A $\beta$  phagocytosis<sup>42-44</sup>. Also, compromised neurovascular profiles have been implicated that dysregulate blood brain barrier permeability and impair the clearance of A $\beta$  from the brain parenchyma<sup>45-49</sup>.

In this thesis, we attempted to characterize how ES exposure impacts these different neurobiological substrates, and how ES can thereby modulate AD phenotypes.

## General experimental design

The nature of our aim necessitates the use of animal experiments<sup>50,51</sup>, that can help provide mechanistic insights emergent at the organismal level<sup>52,53</sup>. Throughout this thesis, we modeled ES in mice using the limited bedding and nesting (LBN) model, first developed in the Baram lab for use in rats<sup>54</sup> and mice<sup>55</sup>. Dams and pups in this model are housed in cages with reduced bedding and nesting materials for the first postnatal week. These ‘impoverished’ conditions limit the dam’s ability to build nests, leading to erratic maternal behavior<sup>55–57</sup>. Pups exposed to these conditions reared until adulthood are reported to have impairments in hypothalamic-pituitary-adrenal axis reactivity<sup>34,55</sup>, adult neurogenesis<sup>58,59</sup>, and cognitive performance across several domains<sup>60</sup>. In the experiments we report here, mice are exposed to ES or control conditions from postnatal days (P) 2-9, and are either sacrificed at P9 to investigate the direct consequences of ES, or transferred to standard housing conditions and sacrificed in adulthood to investigate long term effects of ES.

To more specifically investigate the consequences of ES exposure in relation to AD in a controlled setting, we made use of the APP<sup>swe</sup>/PS1<sup>dE9</sup> transgenic mouse line developed by the Borchelt lab<sup>61</sup>. This model leads to A $\beta$  processing through the prion-promoter-based overexpression of the human amyloid precursor protein (APP) harboring the Swedish mutation, along with the human Presenilin 1 gene with a deletion in exon 9. These mutations result in plaque formation by 6 months of age<sup>61,62</sup>, and are associated with impairments in cognition<sup>63</sup>, synaptic structure<sup>64</sup> and neuroinflammation<sup>65</sup>, among others<sup>66</sup>. Notably, the core phenotype in this model, i.e. a gradual buildup of amyloid load, has been reported to be modulated by ES exposure<sup>67–69</sup>.

Given the age-dependent nature of these effects, we studied the ES and APP/PS1 interaction at both early (4 months of age) and late (10-12 months of age) stages of A $\beta$  pathology. Importantly, beyond serving as a model for AD neuropathology, our APP/PS1 mouse model, which displays a strong neuroimmune response to A $\beta$ <sup>42,63,65</sup>, can also be viewed as a chronic neuroinflammatory challenge that could unmask latent ES effects. We also similarly implemented other forms of secondary challenges, such as aging or restraint, in this thesis in order to unmask ES effects in wildtype mice.

## Neurobiological substrates of interest

We focused in this thesis on the effects of ES and A $\beta$  overexpression on the hippocampus, a brain region important for cognition<sup>70</sup>, in which adult neurogenesis occurs as well<sup>71</sup>.

The hippocampus is strongly affected in AD, exhibiting extensive synaptic loss<sup>41</sup>. It is one of the first regions showing both amyloid and later also tau pathology that spreads through the brain<sup>72,73</sup>. Importantly, the hippocampus contains several cell types<sup>74</sup> that have each been

shown to contribute to AD pathology<sup>41,75,76</sup>. This region is also highly sensitive to stress, due to its relatively enriched expression of glucocorticoid receptors<sup>77,78</sup>. In fact, various types of stress alter hippocampal size<sup>58</sup>, synaptic structure<sup>79,80</sup>, and neurogenesis<sup>81,82</sup>. Altogether, the hippocampus is an interesting brain region due to the consistent disruption of hippocampus-related spatial learning tasks<sup>60</sup> and neurogenesis<sup>83,84</sup> by ES and AD.

In this work, we studied the effects of ES in a transgenic AD mouse model on hippocampal synapses, glial cells, and blood brain barrier features. Below, we first give an overview of these systems, as to how we understand them to be affected by our experimental variables.

### Synapses

As the main functional unit through which neurons communicate, the synapse is an important substrate for all neurobiological questions that is often approached via an investigation of its structural and functional alterations. In particular, in the context of memory, the synapse can be viewed as a neural correlate of learning<sup>85</sup>. Much attention has further been paid recently to the study of synaptic plasticity<sup>86,87</sup>, neurogenesis<sup>88,89</sup>, and the representation of “memory traces” in specific cell ensembles, called engrams<sup>90</sup>.

As mentioned, synaptic loss is a prominent feature of AD pathology, both in early and late stages of the disease<sup>40,91–93</sup>. These effects are partly modulated by direct effects of A $\beta$  on synaptic proteins<sup>38</sup>. While work has been done showing both structural and functional alterations to synapses in rodent models of AD<sup>41,64,72</sup>, the trajectory of these associated alterations is still unknown. On the other hand, ES alters synaptic structure, by reducing synaptic protein levels<sup>94–96</sup>, spine numbers<sup>97</sup>, and neurogenesis<sup>58,98</sup> and function<sup>58,94,99</sup>. However, it remains unknown how ES induces alterations to the overall proteomic profile in hippocampal synapses, and how it would interact with the trajectory of A $\beta$  overexpression-induced synaptic changes.

### Astrocytes

The formation, maturation, and maintenance of synapses is aided by astrocytes<sup>100–103</sup>. While these cells have classically been viewed as passive supporting cells to the neurons, astrocytes can release gliotransmitters that modulate synaptic activity<sup>104,105</sup> and synchronize neuronal network firing<sup>106</sup>. These cells support synaptic functions of neurons largely via their surveillance of the extracellular milieu. This is mediated through different astrocytic receptors, which allow for regulation, e.g., of the levels of neurotransmitters<sup>107,108</sup>, ions<sup>109</sup>, water<sup>110</sup>, and nutrients<sup>101,111</sup>.

Astrocytes also respond to extracellular challenges and play a role in the neuroinflammatory response, e.g. via cytokine release<sup>112</sup>. In such states, they exhibit a “reactive” profile, marked by the upregulation of the astrocytic marker GFAP that underlies the process of astrogliosis<sup>113,114</sup>. Notably, these states can lead to a neurotoxic phenotype<sup>115</sup>, further driving disease states. This is the case in AD, where astrogliosis occurs in response to A $\beta$  plaques<sup>116–119</sup>. These morphological alterations are widespread throughout the main hippocampal subregions and accompanied by spatially heterogeneous astrocytic transcriptomes in the AD brain<sup>120</sup>. Beyond this, astrocytes are also highly sensitive to glucocorticoids and stress<sup>121,122</sup>, which can alter their morphology<sup>123,124</sup>, and glucose metabolism<sup>125,126</sup>. However,

while there is emerging evidence for astrocytes as a substrate for ES effects<sup>127</sup>, it is unclear how ES impacts the astrocytic profile across the lifespan, and how they might be involved in ES modulation of AD.

### **Microglia**

Besides astrocytes, microglia, the innate immune cells in the nervous system, also play a key role in maintaining proper brain function<sup>128</sup>. In healthy states, they survey the extracellular environment<sup>129</sup>, releasing cytokines in response to indicators of extracellular damage such as ATP<sup>130,131</sup>, or phagocytosing apoptotic cells and toxic molecules<sup>132</sup>. Microglia also play a prominent role in a variety of disease states, leading to distinct expression and functional profiles<sup>133</sup>. This microglial adaptation is most evident in neurodegenerative conditions like AD<sup>134</sup>, where mutations in microglial genes can lead to progression of sporadic AD<sup>135</sup>. In fact, microglia can similarly drive disease, as their neuroinflammatory responses<sup>42</sup> can become maladaptive, e.g. worsening pathology by phagocytosing healthy synapses<sup>136</sup>.

Microglia are also among the first functional cell types present in the brain, migrating from the yolk sac during embryonic development<sup>137</sup>. They express distinct gene expression profiles throughout development<sup>138,139</sup>, playing more of a role in sculpting the neuronal architecture and synaptic landscape than inflammatory regulation early in life<sup>140,141</sup>. This early presence of microglia makes them sensitive to early alterations in the brain milieu<sup>142</sup>. Similarly, ES exposure affects microglia, as seen in the transcriptomic changes associated with maternal separation in mice<sup>143</sup>. Studies using the LBN model have also illustrated this, as shown in our work characterizing age-dependent ES effects on microglial morphology and density in the hippocampus in both wildtype and APP/PS1 mice<sup>67</sup>, as well as a study from the Baram lab illustrating ES impairment of microglial synaptic pruning the hypothalamus in wildtype mice<sup>144</sup>.

Important for our research aims, microglia are sensitive to “priming” by prior experiences, as they form an “immunological” memory in their responses to later stimuli<sup>145</sup>. Repeated exposure to immune-activating substances contribute to either milder (i.e. “tolerant”) or exaggerated (i.e., “trained”) responses<sup>146</sup>, the direction of which can be dictated e.g. by the frequency of the immune challenge<sup>147</sup>. Crucially, priming can be induced already even early in life; as seen in the later life response of mice exposed to a prenatal inflammatory environment<sup>148,149</sup>, or in mice injected postnatally with adjuvants consisting of bacterial cell wall extracts<sup>150</sup>. Given the high sensitivity of microglia to stress<sup>151</sup>, one of the outstanding questions in the field is whether ES can also prime later-life microglial function, and whether priming might mediate its effects on the neuroimmune system.

### **Blood-brain barrier**

Lastly, we wanted to investigate the blood brain barrier (BBB), a physical barrier serving as the interface between brain and periphery<sup>152</sup>. The BBB is formed via endothelial cell expression of specific tight junction proteins such as Claudin-5<sup>153</sup>. The surrounding vessel-adjacent cell types are collectively referred to as the neurovascular unit (NVU)<sup>154</sup>. Among the most important processes at the NVU is neurovascular coupling, i.e. the dynamic changes to vascular properties in response to neuronal activity, that are important for energy balance<sup>155</sup>. Disruptions of this balance are notably associated with AD-like cognitive impairments, can



lead to vascular dementias<sup>156</sup>, and may result in brain metabolic alterations, such as seen in AD<sup>157,158</sup>.

Beyond regulating nutrient entry into the brain, the BBB is also implicated in AD through its role in the clearance of A $\beta$ <sup>47</sup>. This process is largely mediated by pathways involving apolipoprotein E<sup>46</sup>, a prominent risk factor for AD<sup>159</sup>. Work on this and other related proteins have demonstrated an emerging role for brain cholesterol metabolism in AD pathology<sup>160</sup>. Crucially, there are strong alterations to both the central and peripheral lipid profiles in ES<sup>99,161,162</sup>. However, despite evidence for stress-associated alterations to BBB function<sup>163,164</sup>, it is currently not known whether and how the BBB is modulated by ES exposure.

### **Interactions between substrates**

Beyond our interest in the ES effects on each system, we also understand that these components are interdependent, and that the effects of ES might be in modulating emergent interactions.

For instance, beyond the well-known recognition of the role of astrocytes in supporting and maintaining the pre- and post-synapse (which together form the “tripartite synapse”)<sup>104,165</sup>, this view has been recently expanded to include microglia (i.e., the “quad-partite” synapse<sup>166,167</sup>). This framework views the long term maintenance of synapse as a result of sculpting from both glial cell types<sup>168</sup>. Beyond the microglial pruning of synapses, the bi-directional signaling between microglia and astrocytes is also important, given e.g. the astrocytic stimulation of microglial phagocytosis<sup>169</sup>, and the observation that activated microglia can in turn, induce neurotoxic, reactive astrocytes<sup>115</sup>.

Similarly, the induction and integrity of the BBB is actively mediated by cells around the neurovascular unit. This is classically done through the signaling of pericytes<sup>170</sup> or astrocytes, whose end feet wrap tightly around endothelial cells<sup>171</sup>. In fact, astrocyte secretion can regulate both vascularization<sup>172,173</sup> and BBB permeability<sup>174,175</sup>, facilitating the coupling of neuronal activity with vascular perfusion discussed above<sup>176</sup>. Crucially, microglia have also recently been shown to be able to impact BBB maintenance in health and disease states<sup>177</sup>.

We expect that these interactions will all contribute to the puzzle of how ES affects the progression of AD pathology. While we were not always able to directly interrogate these interactions, we nonetheless attempted to take them into account in the interpretation of our findings.

### **Aims and outline of this thesis**

As introduced above, this thesis aims to contribute to our understanding of how ES leads to shifts in the developmental trajectories and properties of microglia, synapses, astrocytes, and the blood brain barrier. This will help to understand how ES modulation of AD pathology might occur through these substrates. This thesis is organized as follows:

In **chapter 2**, we test the hypothesis that ES exposure shifts the aging process by comparing wildtype ES and control mice at 20 months of age. We assessed the physiology and cognitive performance behavior of these mice, as well as age-associated hippocampal alterations in neurogenesis, neuroinflammation, and telomere length. By comparing these data with those of younger mice, we attempted to integrate our data into a better understanding of the ES “trajectory”.

In **chapter 3**, we continued our investigation into ES effects on the developmental trajectory by focusing on molecular aspects of aging. In particular, we investigated the hippocampal expression of LaminB1, a nuclear envelope protein whose declining expression is proposed to be a hallmark of aging. We compared how ES exposure affected the overall and astrocytic expression of this protein at 4-, 10-, and 20-months.

In **chapter 4**, we characterized the short- and long-term effects of ES on the hippocampal microglial profile by performing mRNA sequencing on fluorescently-sorted microglia, both at P9 and in adulthood. In line with our questions on developmental trajectories, we also compared how ES altered the pattern of microglial transcriptome changes between P9 and adulthood, as well as how ES modulates the microglial transcriptomic response to a later-life immune challenge. We compliment these findings by adapting an ex vivo flow cytometry assay to assess synaptic phagocytosis in ES microglia, as well as by validating one of our gene expression targets in a postmortem human cohort exposed to childhood abuse.

In **chapter 5**, we investigated the quad-partite synapse, and how ES and A $\beta$  pathology affect this at early and later stages of pathology. We isolated hippocampal synaptosomal fractions and measured the synaptic proteomic composition via mass spectrometry in WT and APP/PS1 mice exposed to ES. We then used electron microscopy and immunofluorescence to validate our findings.

In **chapter 6**, after a better understanding how ES modulated the APP/PS1-induced synaptic alterations, we turned to the last component of the quad-partite synapse, and characterized astrocytes across ages, using qPCR and immunohistochemistry. We compared how these were modulated by ES across ages in the wildtype condition, as well as how ES and APP/PS1 genotype affected these at early and late pathological stages.

In **chapter 7**, we generated a cohort to understand the effects of ES and later-life restraint on the BBB in wildtype mice. We enriched brain endothelial cells to characterize ES effects on blood vessel gene expression, as well as generated tissue for immunofluorescence analysis. We present preliminary data of our immunofluorescence investigations of BBB structure and morphology in ES-exposed mice. We further studied whether this might be a system in which ES alterations of astrocytes also manifest.

In **chapter 8**, we present observations about the ES model used over the past five years, analyzing our data from several rounds of maternal care observation data, and proposing a new readout to validate successful implementation of the LBN model. Additionally, we tackled the well-noted question of how the restriction of nesting material in our model

might alter the temperature of the animals, and whether these might also play roles in the ES phenotype.

Lastly, in **chapter 9**, we provide an interpretation of the different findings in the thesis, and attempt to contextualize these data with the current state of the field. Based on this discussion, we hope to convince the reader that the ES modulation of AD pathology is in part mediated by alterations to these substrates we investigated, as well as their interactions.

## References

1. Saleh A, Potter GG, McQuoid DR, Boyd B, Turner R, MacFall JR, Taylor WD. Effects of early life stress on depression, cognitive performance and brain morphology. *Psychological medicine*. 2017;47(1):171–181.
2. Grainger SA, Crawford JD, Kochan NA, Mather KA, Chander RJ, Draper B, Brodaty H, Sachdev PS, Henry JD. An investigation into early-life stress and cognitive function in older age. *International Psychogeriatrics*. 2020;32(11):1325–1329.
3. Pesonen AK, Eriksson JG, Heinonen K, Kajantie E, Tuovinen S, Alastalo H, Henriksson M, Leskinen J, Osmond C, Barker DJP, Räikkönen K. Cognitive ability and decline after early life stress exposure. *Neurobiology of Aging*. 2013;34(6):1674–1679.
4. Heim C, Newport DJ, Mletzko T, Miller AH, Nemeroff CB. The link between childhood trauma and depression: Insights from HPA axis studies in humans. *Psychoneuroendocrinology*. 2008;33(6):693–710.
5. Miller GE, Chen E, Parker KJ. Psychological Stress in Childhood and Susceptibility to the Chronic Diseases of Aging: Moving Toward a Model of Behavioral and Biological Mechanisms. *Psychological Bulletin*. 2011;137(6):959–997.
6. Entringer S, Wüst S, Kumsta R, Layes IM, Nelson EL, Hellhammer DH, Wadhwa PD. Prenatal psychosocial stress exposure is associated with insulin resistance in young adults. *American Journal of Obstetrics and Gynecology*. 2008;199(5):498.e1–498.e7.
7. Spencer SJ. Early life programming of obesity: the impact of the perinatal environment on the development of obesity and metabolic dysfunction in the offspring. *Current diabetes reviews*. 2012;8(1):55–68.
8. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2013;9(1):63–75.e2.
9. Wimo A, Jönsson L, Bond J, Prince M, Winblad B, Alzheimer Disease International. The worldwide economic impact of dementia 2010. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2013;9(1):1–11.e3.
10. Donley GAR, Lönnroos E, Tuomainen TP, Kauhanen J. Association of childhood stress with late-life dementia and Alzheimer's disease: The KIID study. *European Journal of Public Health*. 2018.
11. Seifan A, Schelke M, Obeng-Aduasare Y, Isaacson R. Early Life Epidemiology of Alzheimer's Disease-A Critical Review. *Neuroepidemiology*. 2015;45(4):237–254.
12. Ravona-Springer R, Beerli MS, Goldbourt U. Younger Age at Crisis Following Parental Death in Male Children and Adolescents Is Associated With Higher Risk for Dementia at Old Age. *Alzheimer Disease & Associated Disorders*. 2012;26(1):68–73.
13. Norton MC, Smith KR, Østbye T, Tschanz JT, Schwartz S, Corcoran C, Breitner JCS, Steffens DC, Skoog I, Rabins P V, Welsh-Bohmer KA. Early Parental Death and Remarriage of Widowed Parents as Risk Factors for Alzheimer Disease. *American Journal of Geriatric Psychiatry*. 2011;19(9):814–824.
14. Wang L, Yang L, Yu L, Song M, Zhao X, Gao Y, Han K, An C, Xu S, Wang X. Childhood physical neglect promotes development of mild cognitive impairment in old age - A case-control study. *Psychiatry Research*. 2016;242(C):13–18.
15. Machado A, Herrera AJ, De Pablos RM, Espinosa-Oliva AM, Sarmiento M, Ayala A, Venero JL, Santiago M, Villarán RF, Delgado-Cortés MJ, Argüelles S, Cano J. Chronic stress as a risk factor for Alzheimer's disease. *Reviews in the Neurosciences*. 2014;25(6):785–804.
16. Caruso A, Nicoletti F, Mango D, Saidi A, Orlando R, Scaccianoce S. Stress as risk factor for Alzheimer's disease. *Pharmacological Research*. 2018;132:130–134.
17. Cline EN, Bicca MA, Viola KL, Klein WL. The Amyloid- $\beta$  Oligomer Hypothesis: Beginning of the Third Decade. *Journal of Alzheimer's Disease*. 2018;64(s1):S567–S610.

18. Liu PP, Xie Y, Meng XY, Kang JS. History and progress of hypotheses and clinical trials for alzheimer's disease. *Signal Transduction and Targeted Therapy*. 2019;4(1):1–22.
19. Karch CM, Goate AM. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. *Biological Psychiatry*. 2015;77(1):43–51.
20. Reitz C, Mayeux R. Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers. *Biochemical Pharmacology*. 2014;88(4):640–651.
21. Andrieu S, Coley N, Lovestone S, Aisen PS, Vellas B. Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. *The Lancet. Neurology*. 2015;14(9):926–944.
22. Poirier J, Miron J, Picard C, Gormley P, Thérroux L, Breitner J, Dea D. Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease. *Neurobiology of Aging*. 2014;35(SUPPL.2):S3–S10.
23. Zawia NH, Basha MR. Environmental risk factors and the developmental basis for Alzheimer's disease. *Reviews in the neurosciences*. 2005;16(4):325–37.
24. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *The Lancet Neurology*. 2010;9(1):119–128.
25. Araújo DC, Veloso AA, Gomes KB, de Souza LC, Ziviani N, Caramelli P. A Novel Panel of Plasma Proteins Predicts Progression in Prodromal Alzheimer's Disease. *Journal of Alzheimer's Disease*. 2022:1–13.
26. Ossenkoppele R, van der Kant R, Hansson O. Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials. *The Lancet Neurology*. 2022.
27. Hawksworth J, Fernández E, Gevaert K. A new generation of AD biomarkers: 2019 to 2021. *Ageing Research Reviews*. 2022;79:101654.
28. Miller DB, O'Callaghan JP. Do early-life insults contribute to the late-life development of Parkinson and Alzheimer diseases? *Metabolism*. 2008;57:S44–S49.
29. Arendt T, Stieler J, Ueberham U. Is sporadic Alzheimer's disease a developmental disorder? *Journal of Neurochemistry*. 2017;143(4):396–408.
30. Lahiri DK, Maloney B. The “LEARn” (Latent Early-Life Associated Regulation) Model: An Epigenetic Pathway Linking Metabolic and Cognitive Disorders. Frisardi V, Imbimbo B, eds. *Journal of Alzheimer's Disease*. 2012;30(s2):S15–S30.
31. Barker DJP, Osmond C, Winter PD, Margetts B, Simmonds SJ. Weight in infancy and death from ischaemic heart disease. *The Lancet*. 1989;334(8663):577–580.
32. Wadhwa PD, Buss C, Entringer S, Swanson JM. Developmental origins of health and disease: Brief history of the approach and current focus on epigenetic mechanisms. *Seminars in Reproductive Medicine*. 2009;27(5):358–368.
33. Liu S, Jones RN, Glymour MM. Implications of lifecourse epidemiology for research on determinants of adult disease. *Public Health Reviews*. 2010;32(2):489–511.
34. Bonapersona V, Damsteegt R, Adams ML, van Weert LTCM, Meijer OC, Joëls M, Sarabdjitsingh RA. Sex-Dependent Modulation of Acute Stress Reactivity After Early Life Stress in Mice: Relevance of Mineralocorticoid Receptor Expression. *Frontiers in Behavioral Neuroscience*. 2019;13:181.
35. Ruigrok SR, Kotah JM, Kuindersma JE, Speijer E, van Irsen AAS, la Fleur SE, Korosi A. Adult food choices depend on sex and exposure to early-life stress: Underlying brain circuitry, adipose tissue adaptations and metabolic responses. *Neurobiology of Stress*. 2021;15.
36. Marrocco J, Gray JD, Kogan JF, Einhorn NR, O'Connie EM, Rubin TG, Carroll TS, Schmidt EF, McEwen BS. Early Life Stress Restricts Translational Reactivity in CA3 Neurons Associated With Altered Stress Responses in Adulthood. *Frontiers in Behavioral Neuroscience*. 2019;13:157.

37. Ruigrok SR, Abbink MR, Geertsema J, Kuindersma JE, Stöberl N, van der Beek EM, Lucassen PJ, Schipper L, Korosi A. Effects of early-life stress, postnatal diet modulation and long-term western-style diet on peripheral and central inflammatory markers. *Nutrients*. 2021;13(2):1–21.
38. Tu S, Okamoto S ichi, Lipton SA, Xu H. Oligomeric A $\beta$ -induced synaptic dysfunction in Alzheimer's disease. *Molecular neurodegeneration*. 2014;9:48.
39. Selkoe DJ. Alzheimer's disease is a synaptic failure. *Science*. 2002;298(5594):789–791.
40. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. *Annals of Neurology*. 1991;30(4):572–580.
41. Scheff SW, Price DA, Schmitt FA, Dekosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. *Neurology*. 2007;68(18):1501–1508.
42. Heneka MT, Carson MJ, Khoury J El, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, et al. Neuroinflammation in Alzheimer's disease. *The Lancet Neurology*. 2015;14(4):388–405.
43. Verkhratsky A, Zorec R, Rodríguez JJ, Parpura V. Astroglia dynamics in ageing and Alzheimer's disease. *Current Opinion in Pharmacology*. 2016;26:74–79.
44. J. Rodríguez J, M. Butt A, Gardenal E, Parpura V, Verkhratsky A. Complex and Differential Glial Responses in Alzheimers Disease and Ageing. *Current Alzheimer Research*. 2016;13(4):343–358.
45. Penke B, Bogár F, F I L.  $\beta$ -amyloid and the pathomechanisms of Alzheimer's disease: A comprehensive view. *Molecules*. 2017;22(10):1692.
46. Bachmeier C, Paris D, Beaulieu-Abdelahad D, Mouzon B, Mullan M, Crawford F. A multifaceted role for apoE in the clearance of beta-amyloid across the blood-brain barrier. *Neurodegenerative Diseases*. 2012;11(1):13–21.
47. Storck SE, Meister S, Nahrath J, Meißner JN, Schubert N, Di Spiezio A, Baches S, Vandenbroucke RE, Bouter Y, Prikulis I, Korth C, Weggen S, Heimann A, Schwaninger M, Bayer TA, et al. Endothelial LRP1 transports amyloid- $\beta$ 1-42 across the blood-brain barrier. *Journal of Clinical Investigation*. 2016;126(1):123–136.
48. Najjar S, Pearlman DM, Devinsky O, Najjar A, Zagzag D. Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: A review of clinical and experimental evidence. *Journal of Neuroinflammation*. 2013;10:1–16.
49. Marques F, Sousa J, Sousa N, Palha J. Blood-brain-barriers in aging and in Alzheimer's disease. *Molecular Neurodegeneration*. 2013;8(1):38.
50. Tsilidis KK, Panagiotou OA, Sena ES, Aretouli E, Evangelou E, Howells DW, Salman RAS, Macleod MR, Ioannidis JPA. Evaluation of Excess Significance Bias in Animal Studies of Neurological Diseases. *PLoS Biology*. 2013;11(7).
51. Jucker M. The benefits and limitations of animal models for translational research in neurodegenerative diseases. *Nature Medicine*. 2010;16(11):1210–1214.
52. Genzel L, Adan R, Berns A, van den Beucken J, Blokland A, Boddeke EHWGM, Bogers WM, Bontrop R, Bulthuis R, Bousema T, Clevers H, Coenen TCJJ, Dam AM van, Deen PMT, van Dijk KW, et al. How the COVID-19 pandemic highlights the necessity of animal research. *Current Biology*. 2020;30(18):R1014–R1018.
53. Homberg JR, Adan RAH, Alenina N, Asiminas A, Bader M, Beckers T, Begg DP, Blokland A, Burger ME, van Dijk G, Eisel ULM, Elgersma Y, Englitz B, Fernandez-Ruiz A, Fitzsimons CP, et al. The continued need for animals to advance brain research. *Neuron*. 2021;109(15):2374–2379.
54. Avishai-Eliner S, Gilles EE, Eghbal-Ahmadi M, Bar-El Y, Baram TZ. Altered regulation of gene and protein expression of hypothalamic-pituitary-adrenal axis components in an immature rat model of chronic stress. *Journal of Neuroendocrinology*. 2001;13(9):799–807.

55. Rice CJ, Sandman CA, Lenjavi MR, Baram TZ. A novel mouse model for acute and long-lasting consequences of early life stress. *Endocrinology*. 2008;149(10):4892–4900.
56. Molet J, Heins K, Zhuo X, Mei YT, Regev L, Baram TZ, Stern H. Fragmentation and high entropy of neonatal experience predict adolescent emotional outcome. *Translational Psychiatry*. 2016;6(1):e702.
57. Knop J, van IJendoorn MH, Bakermans-Kranenburg MJ, Joëls M, van der Veen R. Maternal care of heterozygous dopamine receptor D4 knockout mice: Differential susceptibility to early-life rearing conditions. *Genes, Brain and Behavior*. 2020;19(7).
58. Naninck EFG, Hoeijmakers L, Kakava-Georgiadou N, Meesters A, Lazic SE, Lucassen PJ, Korosi A. Chronic early life stress alters developmental and adult neurogenesis and impairs cognitive function in mice. *Hippocampus*. 2015;25(3):309–328.
59. Abbink MR, Naninck EFG, Lucassen PJ, Korosi A. Early-life stress diminishes the increase in neurogenesis after exercise in adult female mice. *Hippocampus*. 2017;27(8):839–844.
60. Bonapersona V, Kentrop J, Van Lissa CJ, van der Veen R, Joëls M, Sarabdjitsingh RA. The behavioral phenotype of early life adversity: A 3-level meta-analysis of rodent studies. *Neuroscience & Biobehavioral Reviews*. 2019;102:299–307.
61. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. *Biomolecular engineering*. 2001;17(6):157–165.
62. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR. Mutant presenilins specifically elevate the levels of the 42 residue  $\beta$ -amyloid peptide in vivo: evidence for augmentation of a 42-specific  $\gamma$  secretase. *Human Molecular Genetics*. 2004;13(2):159–170.
63. Zhu S, Wang J, Zhang Y, He J, Kong J, Wang J-F, Li X-M. The role of neuroinflammation and amyloid in cognitive impairment in an APP/PS1 transgenic mouse model of Alzheimer's disease. *CNS Neuroscience & Therapeutics*. 2017;23(4):310–320.
64. van der Spek SJF, Gonzalez-Lozano MA, Koopmans F, Miedema SSM, Paliukhovich I, Smit AB, Li KW. Age-dependent hippocampal proteomics in the app/ps1 alzheimer mouse model: A comparative analysis with classical swath/dia and directdia approaches. *Cells*. 2021;10(7).
65. López-González I, Schlüter A, Aso E, Garcia-Esparcia P, Ansoleaga B, Llorens F, Carmona M, Moreno J, Fuso A, Portero-Otin M, Pamplona R, Pujol A, Ferrer I. Neuroinflammatory signals in alzheimer disease and APP/PS1 transgenic mice: Correlations with plaques, tangles, and oligomeric species. *Journal of Neuropathology and Experimental Neurology*. 2015;74(4):319–344.
66. Bilkei-Gorzo A. Genetic mouse models of brain ageing and Alzheimer's disease. *Pharmacology and Therapeutics*. 2014;142(2):244–257.
67. Hoeijmakers L, Ruigrok SR, Amelianchik A, Ivan D, van Dam A-MM, Lucassen PJ, Korosi A. Early-life stress lastingly alters the neuroinflammatory response to amyloid pathology in an Alzheimer's disease mouse model. *Brain, Behavior, and Immunity*. 2017;63:160–175.
68. Lesuis SL, Weggen S, Baches S, Lucassen PJ, Krugers HJ. Targeting glucocorticoid receptors prevents the effects of early life stress on amyloid pathology and cognitive performance in APP/PS1 mice. *Translational Psychiatry*. 2018;8(1):53.
69. Lesuis SL, Kaplick PM, Lucassen PJ, Krugers HJ. Treatment with the glutamate modulator riluzole prevents early life stress-induced cognitive deficits and impairments in synaptic plasticity in APPswe/PS1dE9 mice. *Neuropharmacology*. 2019:1–9.
70. Broadbent NJ, Squire LR, Clark RE. Spatial memory, recognition memory, and the hippocampus. *Proceedings of the National Academy of Sciences of the United States of America*. 2004;101(40):14515–14520.
71. Oomen CA, Bekinschtein P, Kent BA, Saksida LM, Bussey TJ. Adult hippocampal neurogenesis and its role in cognition. *Wiley Interdisciplinary Reviews: Cognitive Science*. 2014;5(5):573–587.

72. Mufson EJ, Mahady L, Waters D, Counts SE, Perez SE, DeKosky ST, Ginsberg SD, Ikonomic MD, Scheff SW, Binder LI. Hippocampal plasticity during the progression of Alzheimer's disease. *Neuroscience*. 2015;309:51–67.
73. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathologica*. 1991;82(4):239–259.
74. Zeisel A, Móz-Manchado AB, Codeluppi S, Lönnerberg P, Manno G La, Juréus A, Marques S, Munguba H, He L, Betsholtz C, Rolny C, Castelo-Branco G, Hjerling-Leffler J, Linnarsson S. Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq. *Science*. 2015;347(6226):1138–1142.
75. Bouvier DS, Murai KK. Synergistic actions of microglia and astrocytes in the progression of Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2015;45(4):1001–1014.
76. Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP, Zhao Z, Toga AW, Jacobs RE, Liu CY, Amezcuca L, Harrington MG, Chui HC, Law M, Zlokovic BV. Blood-Brain Barrier Breakdown in the Aging Human Hippocampus.; 2015.
77. van Steensel B, van Binnendijk EP, Hornsby CD, van der Voort HT, Krozowski ZS, de Kloet ER, van Driel R. Partial colocalization of glucocorticoid and mineralocorticoid receptors in discrete compartments in nuclei of rat hippocampus neurons. *Journal of Cell Science*. 1996;109(4):787–792.
78. McEwen BS, Weiss JM, Schwartz LS. Uptake of corticosterone by rat brain and its concentration by certain limbic structures. *Brain Research*. 1969;16(1):227–241.
79. Cereseto M, Reinés A, Ferrero A, Sifonios L, Rubio M, Wikinski S. Chronic treatment with high doses of corticosterone decreases cytoskeletal proteins in the rat hippocampus. *European Journal of Neuroscience*. 2006;24(12):3354–3364.
80. Castañeda P, Muñoz M, García-Rojo G, Ulloa JL, Bravo JA, Márquez R, García-Pérez MA, Arancibia D, Araneda K, Rojas PS, Mondaca-Ruff D, Díaz-Véliz G, Mora S, Aliaga E, Fiedler JL. Association of N-cadherin levels and downstream effectors of Rho GTPases with dendritic spine loss induced by chronic stress in rat hippocampal neurons. *Journal of Neuroscience Research*. 2015;93(10):1476–1491.
81. Yun J, Koike H, Ibi D, Toth E, Mizoguchi H, Nitta A, Yoneyama M, Ogita K, Yoneda Y, Nabeshima T, Nagai T, Yamada K. Chronic restraint stress impairs neurogenesis and hippocampus-dependent fear memory in mice: possible involvement of a brain-specific transcription factor Npas4. *Journal of Neurochemistry*. 2010;114(6):1840–1851.
82. Barha CK, Brummelte S, Lieblich SE, Galea LAM. Chronic restraint stress in adolescence differentially influences hypothalamic-pituitary-adrenal axis function and adult hippocampal neurogenesis in male and female rats. *Hippocampus*. 2010;21(11):1216–1227.
83. Loi M, Mossink JCL, Meerhoff GF, Den Blaauwen JL, Lucassen PJ, Joëls M. Effects of early-life stress on cognitive function and hippocampal structure in female rodents. *Neuroscience*. 2017;342:101–119.
84. Korosi A, Naninck EFG, Oomen CA, Schouten M, Krugers H, Fitzsimons C, Lucassen PJ. Early-life stress mediated modulation of adult neurogenesis and behavior. *Behavioural brain research*. 2012;227(2):400–9.
85. Mancini A, de lure A, Picconi B. Basic mechanisms of plasticity and learning. In: *Handbook of Clinical Neurology*. Vol 184. Elsevier B.V.; 2022:21–34.
86. Abraham WC, Jones OD, Glanzman DL. Is plasticity of synapses the mechanism of long-term memory storage? *npj Science of Learning*. 2019;4(1).
87. Stacho M, Manahan-Vaughan D. The Intriguing Contribution of Hippocampal Long-Term Depression to Spatial Learning and Long-Term Memory. *Frontiers in Behavioral Neuroscience*. 2022;16.
88. Deng W, Aimone JB, Gage FH. New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory? 2010:1–12.
89. Zhao C, Deng W, Gage FH. Mechanisms and functional implications of adult neurogenesis. *Cell*. 2008;132(4):645–660.



90. Josselyn SA, Tonegawa S. Memory engrams: Recalling the past and imagining the future. *Science*. 2020;367(6473).
91. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW, Morris JC. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. *Neurology*. 2001;56(1):127–129.
92. Scheff SW, Price DA. Synapse loss in the temporal lobe in Alzheimer's disease. *Annals of neurology*. 1993;33(2):190–199.
93. Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. *Neurobiology of Aging*. 2006;27(10):1372–1384.
94. Lesuis SL, Lucassen PJ, Krugers HJ. Early life stress impairs fear memory and synaptic plasticity; a potential role for GluN2B. *Neuropharmacology*. 2019;149:195–203.
95. Liao X-M, Yang X-D, Jia J, Li J-T, Xie X-M, Su Y-A, Schmidt M V., Si T-M, Wang X-D. Blockade of corticotropin-releasing hormone receptor 1 attenuates early-life stress-induced synaptic abnormalities in the neonatal hippocampus. *Hippocampus*. 2014;24(5):528–540.
96. Liu R, Yang XD, Liao XM, Xie XM, Su YA, Li JT, Wang XD, Si TM. Early postnatal stress suppresses the developmental trajectory of hippocampal pyramidal neurons: the role of CRHR1. *Brain Structure and Function*. 2016;221(9):4525–4536.
97. Wang XD, Rammes G, Kraev I, Wolf M, Liebl C, Scharf SH, Rice CJ, Wurst W, Holsboer F, Deussing JM, Baram TZ, Stewart MG, Müller MB, Schmidt M V. Forebrain CRF1 modulates early-life stress-programmed cognitive deficits. *Journal of Neuroscience*. 2011;31(38):13625–13634.
98. Kanatsou S, Karst H, Kortessidou D, Van Den Akker RA, den Blaauwen J, Harris AP, Seckl JR, Krugers HJ, Joels M. Overexpression of mineralocorticoid receptors in the mouse forebrain partly alleviates the effects of chronic early life stress on spatial memory, neurogenesis and synaptic function in the dentate gyrus. *Frontiers in Cellular Neuroscience*. 2017;11:132.
99. Yam KY, Naninck EFG, Abbink MR, la Fleur SE, Schipper L, van den Beukel JC, Grefhorst A, Oosting A, van der Beek EM, Lucassen PJ, Korosi A. Exposure to chronic early-life stress lastingly alters the adipose tissue, the leptin system and changes the vulnerability to western-style diet later in life in mice. *Psychoneuroendocrinology*. 2017;77:186–195.
100. Allen NJ. Role of glia in developmental synapse formation. *Current Opinion in Neurobiology*. 2013;23(6):1027–1033.
101. van Deijk A-LLF, Camargo N, Timmerman J, Heistek T, Brouwers JF, Mogavero F, Mansvelter HD, Smit AB, Verheijen MHG. Astrocyte lipid metabolism is critical for synapse development and function in vivo. *Glia*. 2017;65(4):670–682.
102. Kempermann G. Astrocytes, Makers of New Neurons. *Neuron*. 2015;88(5):850–851.
103. Sultan S, Li L, Moss J, Petrelli F, Cassé F, Gebara E, Lopatar J, Pfrieder FW, Bezzi P, Bischofberger J, Toni N. Synaptic Integration of Adult-Born Hippocampal Neurons Is Locally Controlled by Astrocytes. *Neuron*. 2015;88(5):957–972.
104. Araque A, Parpura V, Sanzgiri RP, Haydon PG. Tripartite synapses: glia, the unacknowledged partner. *Trends in neurosciences*. 1999;22(5):208–215.
105. Ota Y, Zanetti AT, Hallock RM, Ota Y, Zanetti AT, Hallock RM. The role of astrocytes in the regulation of synaptic plasticity and memory formation. *Neural plasticity*. 2013;2013:185463.
106. Fellin T, Pascual O, Haydon PG. Astrocytes Coordinate Synaptic Networks: Balanced Excitation and Inhibition. *Physiology*. 2006;21(3).
107. Robinson MB, Jackson JG. Astroglial glutamate transporters coordinate excitatory signaling and brain energetics. *Neurochemistry International*. 2016;98:56–71.
108. Parpura V, Verkhratsky A. Homeostatic function of astrocytes: Ca<sup>2+</sup> and Na<sup>+</sup> signalling. *Translational Neuroscience*. 2012;3(4):118–193.

109. Hertz L, Chen Y. Importance of astrocytes for potassium ion (K<sup>+</sup>) homeostasis in brain and glial effects of K<sup>+</sup> and its transporters on learning. *Neuroscience & Biobehavioral Reviews*. 2016;71:484–505.
110. Potokar M, Jorgačevski J, Zorec R. Astrocyte Aquaporin Dynamics in Health and Disease. *International journal of molecular sciences*. 2016;17(7).
111. Falkowska A, Gutowska I, Goschorska M, Nowacki P, Chlubek D, Baranowska-Bosiacka I. Energy Metabolism of the Brain, Including the Cooperation between Astrocytes and Neurons, Especially in the Context of Glycogen Metabolism. *International Journal of Molecular Sciences*. 2015;16(11):25959–25981.
112. Dong Y, Benveniste EN. Immune function of astrocytes. *Glia*. 2001;36(2):180–190.
113. Hol EM, Pekny M. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. *Current opinion in cell biology*. 2015;32:121–130.
114. Pekny M, Pekna M. Astrocyte Reactivity and Reactive Astrogliosis: Costs and Benefits. *Physiological Reviews*. 2014;94(4):1077–1098.
115. Liddel SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, Münch AE, Chung W-SS, Peterson TC, Wilton DK, Frouin A, Napier BA, Panicker N, Kumar M, et al. Neurotoxic reactive astrocytes are induced by activated microglia. *Nature*. 2017;541(7638):481–487.
116. Kamphuis W, Middeldorp J, Kooijman L, Sluijs JA, Kooi E-J, Moeton M, Freriks M, Mizee MR, Hol EM. Glial fibrillary acidic protein isoform expression in plaque related astrogliosis in Alzheimer's disease. *Neurobiology of Aging*. 2014;35(3):492–510.
117. Kato S, Gondo T, Hoshii Y, Takahashi M, Yamada M, Ishihara T. Confocal observation of senile plaques in Alzheimer's disease: senile plaque morphology and relationship between senile plaques and astrocytes. *Pathology international*. 1998;48(5):332–340.
118. Osborn LM, Kamphuis W, Wadman WJ, Hol EM. Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease. *Progress in Neurobiology*. 2016;144:121–141.
119. Vijayan VK, Gedes JW, Anderson KJ, Chang-Chui H, Ellis WG, Cotman CW. Astrocyte hypertrophy in the Alzheimer's disease hippocampal formation. *Experimental Neurology*. 1991;112(1):72–78.
120. Sadick JS, O'Dea MR, Hasel P, Dykstra T, Faustin A, Liddel SA. Astrocytes and oligodendrocytes undergo subtype-specific transcriptional changes in Alzheimer's disease. *Neuron*. 2022;110(11):1788-1805.e10.
121. Pretorius E, Marx J. Direct and indirect effects of corticosteroids on astrocyte function. *Reviews in the neurosciences*. 2004;15(3):199–207.
122. Czéh B, Simon M, Schmeltz B, Hiemke C, Fuchs E. Astroglial Plasticity in the Hippocampus is Affected by Chronic Psychosocial Stress and Concomitant Fluoxetine Treatment. *Neuropsychopharmacology*. 2006;31(8):1616–1626.
123. O'Callaghan JP, Brinton RE, McEwen BS. Glucocorticoids regulate the concentration of glial fibrillary acidic protein throughout the brain. *Brain Research*. 1989;494(1):159–161.
124. Zhao Y, Wang Z. Chronic corticosterone exposure reduces hippocampal astrocyte structural plasticity and induces hippocampal atrophy in mice. *Neuroscience Letters*. 2015;592:76–81.
125. Tombaugh GC, Yang SH, Swanson RA, Sapolsky RM. Glucocorticoids Exacerbate Hypoxic and Hypoglycemic Hippocampal Injury In Vitro: Biochemical Correlates and a Role for Astrocytes. *Journal of Neurochemistry*. 1992;59(1):137–146.
126. Virgin CE, Ha TP, Packan DR, Tombaugh GC, Yang SH, Horner HC, Sapolsky RM. Glucocorticoids inhibit glucose transport and glutamate uptake in hippocampal astrocytes: implications for glucocorticoid neurotoxicity. *Journal of Neurochemistry*. 1991;57(4):1422–1428.
127. Abbink MR, van Deijk A-LF, Heine VM, Verheijen MH, Korosi A. The involvement of astrocytes in early-life adversity induced programming of the brain. *Glia*. 2019;67(9):1637–1653.
128. Sierra A, Paolicelli RC, Kettenmann H. Cien Años de Microglía: Milestones in a Century of Microglial Research. *Trends in Neurosciences*. 2019;42(11):778–792.

129. Nimmerjahn A. Resting Microglial Cells Are Highly Dynamic Surveillants of Brain Parenchyma in Vivo. *Science*. 2005;308(5726):1314–1318.
130. Davalos D, Grutzendler J, Yang G, Kim J V., Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB. ATP mediates rapid microglial response to local brain injury in vivo. *Nature Neuroscience*. 2005;8(6):752–758.
131. Madry C, Kyrargyri V, Arancibia-Cárcamo IL, Jolivet R, Kohsaka S, Bryan RM, Attwell D. Microglial Ramification, Surveillance, and Interleukin-1 $\beta$  Release Are Regulated by the Two-Pore Domain K<sup>+</sup> Channel THIK-1. *Neuron*. 2018;97(2):299–312.e6.
132. Tajbakhsh A, Read M, Barreto GE, Ávila-Rodríguez M, Gheibi-Hayat SM, Sahebkar A. Apoptotic neurons and amyloid-beta clearance by phagocytosis in Alzheimer's disease: Pathological mechanisms and therapeutic outlooks. *European Journal of Pharmacology*. 2021;895.
133. Butovsky O, Weiner HL. Microglial signatures and their role in health and disease. *Nature Reviews Neuroscience*. 2018;19(10):622–635.
134. Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O'Loughlin E, Xu Y, Fanek Z, Greco DJ, Smith ST, Tweet G, Humulock Z, Zrzavy T, et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. *Immunity*. 2017;47(3):566–581.e9.
135. Efthymiou AG, Goate AM. Late onset Alzheimer's disease genetics implicates microglial pathways in disease risk. *Molecular Neurodegeneration*. 2017;12(1).
136. Paolicelli RC, Jawaid A, Henstridge CM, Valeri A, Merlini M, Robinson JL, Lee EB, Rose J, Appel S, Lee VMY, Trojanowski JQ, Spires-Jones T, Schulz PE, Rajendran L. TDP-43 Depletion in Microglia Promotes Amyloid Clearance but Also Induces Synapse Loss. *Neuron*. 2017;95(2):297–308.e6.
137. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, Samokhvalov IM, Merad M. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. *Science*. 2010;330(6005):841–845.
138. Matcovitch-Natan O, Winter DR, Giladi A, Vargas Aguilar S, Spinrad A, Sarrazin S, Ben-Yehuda H, David E, Zelada Gonzalez F, Perrin P, Keren-Shaul H, Gury M, Lara-Astaiso D, Thaiss CA, Cohen M, et al. Microglia development follows a stepwise program to regulate brain homeostasis. *Science*. 2016;353(6301):aad8670.
139. Kracht L, Borggrewe M, Eskandar S, Brouwer N, Chuva de Sousa Lopes SM, Laman JD, Scherjon SA, Prins JR, Kooistra SM, Eggen BJL. Human fetal microglia acquire homeostatic immune-sensing properties early in development. *Science*. 2020;369(6503):530–537.
140. Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, Ransohoff RM, Greenberg ME, Barres BA, Stevens B. Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner. *Neuron*. 2012;74(4):691–705.
141. Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, Giustetto M, Ferreira TA, Guiducci E, Dumas L, Ragozzino D, Gross CT. Synaptic pruning by microglia is necessary for normal brain development. *Science*. 2011;333(6048):1456–1458.
142. Madore C, Leyrolle Q, Morel L, Rossitto M, Greenhalgh AD, Delpech JC, Martinat M, Bosch-Bouju C, Bourel J, Rani B, Lacabanne C, Thomazeau A, Hopperton KE, Beccari S, Sere A, et al. Essential omega-3 fatty acids tune microglial phagocytosis of synaptic elements in the mouse developing brain. *Nature Communications*. 2020;11(1):6133.
143. Delpech J-CC, Wei L, Hao J, Yu X, Madore C, Butovsky O, Kaffman A. Early life stress perturbs the maturation of microglia in the developing hippocampus. *Brain Behavior and Immunity*. 2016;57(C):79–93.
144. Bolton JL, Short AK, Othy S, Kooiker CL, Shao M, Gunn BG, Beck J, Bai X, Law SM, Savage JC, Lambert JJ, Belelli D, Tremblay M-È, Cahalan MD, Baram TZ. Early stress-induced impaired microglial pruning of excitatory synapses on immature CRH-expressing neurons provokes aberrant adult stress responses. *Cell Reports*. 2022;38(13):110600.

145. Neher JJ, Cunningham C. Priming Microglia for Innate Immune Memory in the Brain. *Trends in Immunology*. 2019;40(4):358–374.
146. Heng Y, Zhang X, Borggrewe M, van Weering HRJ, Brummer ML, Nijboer TW, Joosten LAB, Netea MG, Boddeke EWGM, Laman JD, Eggen BJL. Systemic administration of  $\beta$ -glucan induces immune training in microglia. *Journal of Neuroinflammation*. 2021;18(1):57.
147. Wendeln AC, Degenhardt K, Kaurani L, Gertig M, Ulas T, Jain G, Wagner J, Häsler LM, Wild K, Skodras A, Blank T, Staszewski O, Datta M, Centeno TP, Capece V, et al. Innate immune memory in the brain shapes neurological disease hallmarks. *Nature*. 2018;556(7701):332–338.
148. Knuesel I, Chicha L, Britschgi M, Schobel SA, Bodmer M, Hellings JA, Toovey S, Prinssen EP. Maternal immune activation and abnormal brain development across CNS disorders. *Nature Reviews Neurology*. 2014;10(11):643–660.
149. Schaafsma W, Basterra LB, Jacobs S, Brouwer N, Meerlo P, Schaafsma A, Boddeke EWGM, Eggen BJL. Maternal inflammation induces immune activation of fetal microglia and leads to disrupted microglia immune responses, behavior, and learning performance in adulthood. *Neurobiology of Disease*. 2017;106:291–300.
150. Bilbo SD, Schwarz JM. Early-life programming of later-life brain and behavior: A critical role for the immune system. *Frontiers in Behavioral Neuroscience*. 2009;3(AUG):14.
151. Sanguino-Gómez J, Buurstede JC, Abiega O, Fitzsimons CP, Lucassen PJ, Eggen BJL, Lesuis SL, Meijer OC, Krugers HJ. An emerging role for microglia in stress-effects on memory. *European Journal of Neuroscience*. 2022;55(9–10):2491–2518.
152. Abbott NJ. Dynamics of CNS barriers: Evolution, differentiation, and modulation. *Cellular and Molecular Neurobiology*. 2005;25(1):5–23.
153. Greene C, Hanley N, Campbell M. Claudin-5: Gatekeeper of neurological function. *Fluids and Barriers of the CNS*. 2019;16(1):1–15.
154. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. *Neurobiology of Disease*. 2010;37(1):13–25.
155. De Vries E, Prat A. The blood-brain barrier and its microenvironment: Basic physiology to neurological disease.; 2005.
156. Li C, Wang Y, Yan XL, Guo ZN, Yang Y. Pathological changes in neurovascular units: Lessons from cases of vascular dementia. *CNS Neuroscience and Therapeutics*. 2021;27(1):17–25.
157. Ardanaz CG, Ramírez MJ, Solas M. Brain Metabolic Alterations in Alzheimer’s Disease. *International Journal of Molecular Sciences*. 2022;23(7).
158. Sweeney MD, Sagare AP, Zlokovic B V. Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. *Nature Reviews Neurology*. 2018.
159. Yu J-T, Tan L, Hardy J. Apolipoprotein E in Alzheimer’s Disease: An Update. *Annual Review of Neuroscience*. 2014;37(1):79–100.
160. Lim WLF, Martins IJ, Martins RN. The involvement of lipids in alzheimer’s disease. *Journal of Genetics and Genomics*. 2014;41(5):261–274.
161. Yam KY, Schipper L, Reemst K, Ruigrok SR, Abbink MR, Hoeijmakers L, Naninck EFG, Zarekiani P, Oosting A, Van Der Beek EM, Lucassen PJ, Korosi A. Increasing availability of  $\omega$ -3 fatty acid in the early-life diet prevents the early-life stress-induced cognitive impairments without affecting metabolic alterations. *FASEB Journal*. 2019;33(4):5729–5740.
162. Ruigrok SR, Abbink MR, Geertsema J, Kuindersma JE, Stöberl N, van der Beek EM, Lucassen PJ, Schipper L, Korosi A. Effects of early-life stress, postnatal diet modulation and long-term western-style diet on peripheral and central inflammatory markers. *Nutrients*. 2021;13(2):1–21.

163. Menard C, Pfau ML, Hodes GE, Kana V, Wang VX, Bouchard S, Takahashi A, Flanigan ME, Aleyasin H, LeClair KB, Janssen WG, Labonté B, Parise EM, Lorsch ZS, Golden SA, et al. Social stress induces neurovascular pathology promoting depression HHS Public Access Author manuscript. *Nature Neuroscience*. 2017;20(12):1752–1760.
164. Sántha P, Veszelka S, Hoyk Z, Mészáros M, Walter FR, Tóth AE, Kiss L, Kincses A, Oláh Z, Seprényi G, Rákhely G, Dér A, Pákási M, Kálmán J, Kittel Á, et al. Restraint Stress-Induced Morphological Changes at the Blood-Brain Barrier in Adult Rats. *Frontiers in Molecular Neuroscience*. 2016;8:88.
165. Araque A, Parpura V, Sanzgiri RP, Haydon PG. Glutamate-dependent astrocyte modulation of synaptic transmission between cultured hippocampal neurons. *European Journal of Neuroscience*. 1998;10(6):2129–2142.
166. Rial D, Lemos C, Pinheiro H, Duarte JM, Gonçalves FQ, Real JI, Prediger RD, Gonçalves N, Gomes CA, Canas PM, Agostinho P, Cunha RA. Depression as a Glial-Based Synaptic Dysfunction. *Frontiers in Cellular Neuroscience*. 2016;9:521.
167. Schafer DP, Lehrman EK, Stevens B. The “quad-partite” synapse: Microglia-synapse interactions in the developing and mature CNS. *GLIA*. 2013;61(1):24–36.
168. Sheridan GK, Murphy KJ. Neuron-glia crosstalk in health and disease: Fractalkine and CX3CR1 take centre stage. *Open Biology*. 2013;3(1 DEC):130181.
169. Vainchtein ID, Chin G, Cho FS, Kelley KW, Miller JG, Chien EC, Liddelow SA, Nguyen PT, Nakao-Inoue H, Dorman LC, Akil O, Joshita S, Barres BA, Paz JT, Molofsky AB, et al. Astrocyte-derived interleukin-33 promotes microglial synapse engulfment and neural circuit development. *Science*. 2018;359(6381):1269–1273.
170. Daneman R, Zhou L, Kebede AA, Barres BA. Pericytes are required for blood–brain barrier integrity during embryogenesis. *Nature*. 2010;468(7323):562–566.
171. Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. *Nature Reviews Neuroscience*. 2006;7(1):41–53.
172. Argaw AT, Asp L, Zhang J, Navrazhina K, Pham T, Mariani JN, Mahase S, Dutta DJ, Seto J, Kramer EG, Ferrara N, Sofroniew M V., John GR. Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. *Journal of Clinical Investigation*. 2012;122(7):2454–2468.
173. Argaw AT, Gurfein BT, Zhang Y, Zameer A, John GR. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. *Proceedings of the National Academy of Sciences of the United States of America*. 2009;106(6):1977–1982.
174. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A, Sallstrom J, Berk BC, Zlokovic B V. Apolipoprotein e controls cerebrovascular integrity via cyclophilin A. *Nature*. 2012;485(7399):512–516.
175. Jackson RJ, Meltzer JC, Nguyen H, Commins C, Bennett RE, Hudry E, Hyman BT. APOE4 derived from astrocytes leads to blood–brain barrier impairment. *Brain*. 2021.
176. Attwell D, Buchan AM, Charpak S, Lauritzen M, MacVicar BA, Newman EA. Glial and neuronal control of brain blood flow. *Nature*. 2010;468(7321):232–243.
177. Haruwaka K, Ikegami A, Tachibana Y, Ohno N, Konishi H, Hashimoto A, Matsumoto M, Kato D, Ono R, Kiyama H, Moorhouse AJ, Nabekura J, Wake H. Dual microglia effects on blood brain barrier permeability induced by systemic inflammation. *Nature communications*. 2019;10(1):5816.